These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24602025)

  • 1. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
    Picard M; Pham Dang N; D'Incan M; Mansard S; Dechelotte P; Pereira B; Mondie JM; Barthelemy I
    Br J Dermatol; 2014 Jul; 171(1):108-14. PubMed ID: 24602025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation screening in melanoma: is sentinel lymph node reliable?
    Nardin C; Puzenat E; Prétet JL; Algros MP; Doussot A; Puyraveau M; Mougin C; Aubin F
    Melanoma Res; 2015 Aug; 25(4):328-34. PubMed ID: 26020488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
    Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
    Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study.
    Pasquali S; Mocellin S; Mozzillo N; Maurichi A; Quaglino P; Borgognoni L; Solari N; Piazzalunga D; Mascheroni L; Giudice G; Patuzzo R; Caracò C; Ribero S; Marone U; Santinami M; Rossi CR
    J Clin Oncol; 2014 Mar; 32(9):935-41. PubMed ID: 24516022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
    Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
    Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes.
    Kunte C; Geimer T; Baumert J; Konz B; Volkenandt M; Flaig M; Ruzicka T; Berking C; Schmid-Wendtner MH
    J Am Acad Dermatol; 2011 Apr; 64(4):655-62; quiz 637. PubMed ID: 21315477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and location of positive nonsentinel lymph nodes in head and neck melanoma.
    Gyorki DE; Boyle JO; Ganly I; Morris L; Shaha AR; Singh B; Wong RJ; Shah JP; Busam K; Kraus D; Coit DG; Patel S
    Eur J Surg Oncol; 2014 Mar; 40(3):305-10. PubMed ID: 24361245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
    Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
    Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
    Keijzer R; Bril H; van der Loo EM; de Graaf PW
    Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of BRAF mutations in primary melanoma growth rate and survival.
    Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
    Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
    Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
    Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognosis after sentinel node biopsy in malignant melanoma].
    Lock-Andersen J; Horn J; Sjøstrand H
    Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutation-positive folliculotropic metastatic melanoma.
    Brick KE; Halling KC; Khan YK; Peters MS
    Am J Dermatopathol; 2013 Jul; 35(5):609-12. PubMed ID: 23715079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.